U.S. Communications Stock News

eInfochips, a subsidiary of Arrow Electronics (NYSE:ARW), has launched NomAIzo, a suite of AI-focused platforms, frameworks, and services. NomAIzo is designed to help customers accelerate edge to enterprise AI adoption across use cases from devices to the cloud. The launch expands Arrow Electronics' presence in AI and high tech engineering services by broadening its edge to cloud offering. For you as an investor, NomAIzo ties directly into what Arrow Electronics already does across...

Lamar Advertising recently declared a past quarterly cash dividend of US$1.60 per share, payable on March 31, 2026, and extended its stock and debt repurchase programs, each authorizing up to US$250.00 million through September 30, 2027. These moves highlight management’s focus on returning capital to shareholders while signaling confidence in the company’s balance sheet and cash-generation capacity. Now we’ll examine how the extended stock repurchase authorization influences Lamar’s...

Relay Therapeutics FY 2025 earnings: revenue modest, losses continue as investors focus on growth potential Relay Therapeutics (RLAY) has wrapped up FY 2025 with Q4 revenue of US$7 million, a basic EPS loss of US$0.32, and net income loss of US$54.89 million, keeping the story firmly in loss-making territory as the market weighs its growth profile. The company has seen quarterly revenue move between US$0 million and US$7.68 million over the past year, while basic EPS losses have ranged from...

In late February 2026, Ferguson Enterprises Inc. reported past fourth-quarter sales of US$7,495 million and net income of US$389 million, alongside five‑month sales of US$12,833 million and net income of US$786 million, while also outlining low‑ to mid‑single‑digit net sales growth expectations for the 2026 calendar year. Along with these results, Ferguson continued to return cash to shareholders through US$248.45 million of share repurchases completing a multi‑year US$4.49 billion program...

In February 2026, Expeditors International of Washington reported fourth-quarter 2025 results showing revenue of US$2,855.95 million and net income of US$200.71 million, alongside authorizing a new US$3.00 billion share repurchase program and completing a long-running US$8.72 billion buyback. While full-year 2025 revenue and earnings per share grew modestly, weaker ocean freight performance and higher headcount weighed on quarterly profitability. We will now examine how softer ocean freight...

Conference update and pipeline focus Corvus Pharmaceuticals (CRVS) has come into focus after its appearance at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, where management outlined fresh details on lead candidate soquelitinib across several immune related indications. The company highlighted plans for a phase III interim analysis in peripheral T cell lymphoma by year end 2026, new phase II studies in asthma and hidradenitis suppurativa, and early atopic dermatitis data...

Central Garden & Pet reported a 6% year over year revenue decline in its latest quarter. The company expanded its share repurchase program, signaling an increased focus on buybacks. Central Garden & Pet also refreshed its board of directors with new appointments. Central Garden & Pet, traded as NasdaqGS:CENT, released results that showed weaker revenue and earnings alongside the slowest revenue growth among its household product peers. The stock last closed at $39.18 and is up 22.1% over...

If you are wondering whether Universal Health Services is attractively priced or starting to look expensive, you are in the right place for a clear look at what the market might be implying about its value. The shares last closed at US$206.10, with returns of a 10.6% decline over 7 days, 1.5% over 30 days, a 6.3% decline year to date, 18.1% over 1 year, 64.2% over 3 years, and 61.1% over 5 years. This gives you a broad sense of how sentiment around the stock has shifted over time. Recent...

ON Semiconductor is sharpening its focus on higher margin areas, including silicon carbide products and AI data center power solutions. The company is reallocating capital toward projects it views as higher return and scaling back exposure to weaker end markets such as electric vehicles and smartphones. Management is emphasizing capital discipline and targeted investment as it reshapes the business mix of NasdaqGS:ON. For investors tracking NasdaqGS:ON, this reset comes with the stock...

Coastal Financial recently reported a past-quarter update showing a 1.3% year-on-year revenue decline, missing analysts’ expectations by 16.6%, even as loans receivable grew 1.2% and deposits rose 4.3%. Management emphasized the potential of its Banking-as-a-Service platform, highlighting plans to expand product offerings and scale new and existing partnerships despite the disappointing revenue and net interest income performance. We’ll now examine how Coastal Financial’s revenue shortfall...

Vera Therapeutics reported full-year 2025 results showing a net loss of US$299.62 million, while advancing atacicept with positive Phase 3 IgA nephropathy data and securing FDA priority review with a July 7, 2026 PDUFA date. Alongside filing a US$191.89 million Class A common stock shelf registration for an ESOP-related offering, the company highlighted that its cash, equivalents, marketable securities and debt facility availability are expected to fund operations through potential atacicept...

Pulse Biosciences, Inc. reported a full-year 2025 net loss of US$72.78 million, widening from US$53.59 million in 2024, and filed new universal and ESOP-related shelf registrations alongside a reconfigured at-the-market common stock offering. At the same time, FDA approval to begin a paroxysmal atrial fibrillation study with the nPulse Cardiac Catheter System and a planned thyroid cancer collaboration with The University of Texas MD Anderson Cancer Center underscore how the company is...

The Honest Company, Inc. recently reported that full-year 2025 sales slipped to US$371.32 million while net loss more than doubled to US$15.69 million, and simultaneously announced a new US$25 million share repurchase program funded by cash on hand and operating cash flows. Alongside this, management issued 2026 guidance calling for an anticipated high-teens percentage decline in reported revenue due to exited categories, while emphasizing 4% to 6% organic growth as the core metric of its...

If you are wondering whether Evercore's current share price fairly reflects its underlying worth, you are not alone. This article is designed to help you size that up clearly. The stock last closed at US$308.84, with returns of 29.2% over 1 year and a 144.5% gain over 3 years, even though the past 7 days and 30 days show declines of 5.9% and 15.0% and the year to date return sits at a 12.1% decline. Recent coverage has focused on Evercore's role as a major independent investment bank in...

If you are wondering whether Vistance Networks at around US$17.57 still offers value after a strong run, this article will help you size up the price against the fundamentals. The stock has pulled back with a 7.4% decline over the last week and a 6.5% decline over the last 30 days, yet it still sits on a 176.7% return over the past year and 125.3% over three years. Recent price moves come as the market continues to react to ongoing news flow around Vistance Networks, including growing...

Enact Holdings, Inc. has recently outlined in its 2025 10-K a new US$350 million share repurchase authorization and a US$435 million revolving credit facility, alongside continued plans to return capital via dividends and buybacks while supporting its U.S. mortgage insurance operations. Analyst sentiment has shifted as Enact was elevated to a Zacks Rank #1 (Strong Buy) on the back of higher earnings estimates, underscoring how its capital return plans and financing flexibility are...

In late February 2026, Marsh & McLennan Companies’ board declared a US$0.900 quarterly dividend per share and secured a court injunction protecting its confidential information, while also adding experienced investment executive Peter Harrison to its now 13‑member board. Together, the legal victory, board refresh, and continued capital return program underscore how Marsh & McLennan is reinforcing both its governance framework and protection of core client and data relationships. We’ll now...

Albertsons Companies (NYSE:ACI) has appointed experienced technology executive Brian Rice to its Board of Directors. Rice brings a background in digital transformation, technology leadership, and global supply chain operations at major consumer brands including McDonald's. The board change highlights a focus on technology, digital engagement, and cybersecurity for the grocery retailer. Albertsons, one of the largest food and drug retailers in the United States, operates a wide network of...

Nordson (NasdaqGS:NDSN) reported strong Q1 earnings, followed by several analyst upgrades. Shortly after these results, the CEO and Executive Vice President executed significant insider share sales. The timing of these transactions, coming on the heels of upbeat quarterly news, has drawn investor attention. Nordson, a producer of precision dispensing and related technologies, operates at the intersection of industrial, electronics, and consumer end markets. Many of its customers use Nordson...

Nordic American Tankers (NAT) has rounded out FY 2025 with Q4 revenue of US$59.5 million and net income of US$11.7 million, equal to EPS of about US$0.06, against a trailing 12 month EPS figure of roughly US$0.06 on revenue of US$183.3 million. The company has recorded quarterly revenue between US$37.9 million and US$59.5 million over 2025, while EPS has ranged from a small loss of about US$0.01 to a gain of roughly US$0.06. This has set up a results season in which investors are paying close...

In recent months, Viking Therapeutics has advanced its dual GLP-1/GIP obesity candidate VK2735 into late-stage trials while a rival program, Novo Nordisk’s CagriSema, missed a key goal in late-stage testing. This combination of competitor setbacks and Viking’s progress, including plans for both injectable and oral VK2735 formulations, has sharpened investor focus on the company’s role in the obesity treatment race. With VK2735 moving into phase 3 trials, we’ll now examine how this...

In recent days, Glacier Bancorp was caught up in a broader selloff of regional banks after hotter‑than‑expected January Producer Price Index data heightened concerns about persistent inflation and credit risks. This bout of risk aversion has pushed investors to scrutinize how exposed banks like Glacier are to cyclical sectors, private credit, and leveraged loans. We’ll now examine how renewed worries about sticky inflation and credit risk could influence Glacier Bancorp’s previously...

MARA Holdings, NasdaqCM:MARA, is shifting its core business from Bitcoin mining to AI and high performance computing infrastructure. The company has entered a joint venture with Starwood Capital Group and Starwood Digital Ventures to convert and expand its existing power heavy sites. The partnership also includes acquiring a majority stake in Exaion to support international data center expansion. MARA Holdings is moving away from a pure Bitcoin mining model and into digital infrastructure...

Cleveland-Cliffs recently appointed Ralph “Mike” Michael III as Lead Independent Director and named Edilson Camara Chairman of the Compensation and Organization Committee, following Douglas Taylor’s resignation under the company’s mandatory resignation policy tied to changes in a director’s primary occupation. With a seasoned leadership advisor now guiding compensation decisions and an experienced independent director leading the board, Cleveland-Cliffs is reinforcing its governance...